Lacosamide Stada

Lacosamide, the active ingredient in Lacosamide Stada, is an anticonvulsant presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide Stada is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures: reduces the frequency of focal seizures when used as adjunct therapy. Epilepsy: helps achieve better overall seizure control in patients with epilepsy. Adjunctive therapy for refractory epilepsy: provides additional seizure reduction when first‑line agents are insufficient.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Blurred vision - Diplopia

Serious or Rare Side Effects: - PR‑interval prolongation or other cardiac conduction abnormalities - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Hypersensitivity reactions including anaphylaxis - Elevated liver enzymes - Severe respiratory depression when combined with other CNS depressants

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: risk unknown; discuss benefits versus risks with the patient. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacosamide plasma levels. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): risk of additive cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce lacosamide efficacy. - Phenytoin: may increase risk of dizziness and ataxia. - Alcohol or other CNS depressants: monitor for enhanced sedation. - Certain antidepressants (e.g., SSRIs): watch for increased side‑effect burden.